CHRS
Signal
Bearish Setup2
Price
1
Move-3.68%Selling pressure
Volume
1
Volume1.2× avgNormal activity
Technical
1
RSIRSI 48Momentum negative
Next earnings: Aug 6, 2026 · After close
ANALYST COVERAGE16 analysts
BUY
+282.2%upside to target
L $1.05
Med $6.00consensus
H $11.00
Buy
1381%
Hold
319%
13 Buy (81%)3 Hold (19%)0 Sell (0%)
Full report →
PRICE
Prev Close
1.63
Open
1.61
Day Range1.56 – 1.65
1.56
1.65
52W Range0.71 – 2.62
0.71
2.62
45% of range
VOLUME & SIZE
Avg Volume
1.3M
FUNDAMENTALS
P/E Ratio
-1.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.48
Market-like
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 106 days
Aug 31
Key MetricsTTM
Market Cap$192.18M
Revenue TTM$46.88M
Net Income TTM-$151.66M
Free Cash Flow-$170.57M
Gross Margin60.0%
Operating Margin-362.1%
Net Margin-323.5%
Return on Equity-174.7%
Return on Assets-57.0%
Debt / Equity0.69
Current Ratio1.56
EPS TTM$-1.11

CHRS News

About

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Dennis Lanfear
Andy RittenbergChief Legal Officer
Sameer GoregaokerChief Commercial Officer
Theresa LavalleeChief Development Officer & Chairman of Scientific Advisory Board
Arvind SoodChief Strategy & Corporate Affairs Officer
Bryan J. McMichaelChief Financial Officer
Dennis LanfearChairman, President & Chief Executive Officer
Michael ChenSenior Vice President of Commercial Analytics & Trade
Carrie GrahamVice President of Investor Relations & Advocacy
Rebecca SunshineChief Human Resources Officer
Rosh Dias MRCPChief Medical Officer